(Q54335451)

English

Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium.

scientific article published on 24 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

multicenter clinical trial

1 reference

based on heuristic

0 references

Philip R. Debruyne

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

author name string

N Cornelis

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

T Vermassen

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

D Schallier

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

J-P Machiels

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

T Gil

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

R D'hondt

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

A Bols

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

D Schrijvers

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

J Mebis

10

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

N Lumen

11

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

S Rottey

12

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

publication date

24 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

Acta Clinica Belgica

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

69

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

335-340

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1179%2F2295333714Y.0000000051

21 January 2018

Identifiers

10.1179/2295333714Y.0000000051

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/25056491

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54335451&oldid=1403927803"